Updated hourlyHourly refreshTue, Oct 27, 2026
Finance · Healthcare
CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
Oct 9 · 20:30·GlobeNewswire
Finance · Biotech & pharma
AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee’s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.
Oct 9 · 20:15·GlobeNewswire
Finance · Healthcare
Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
Tue, 10/13/2026 - 08:15
Body
Originally published on CVS Health Company Newsroom
HARTFORD, Conn., October 13, 2026 - Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). These results position Aetna as one of the highest-performing large, publicly traded Medicare Advantage organizations in the Star Ratings program for the third consecutive year and highlight strong performance across various clinical quality, preventive care and member experience measures.
"For years, Aetna has been a leader in Star Ratings, and this year's results highlight our distinction in the market," said Steve Nelson, President of Aetna. "We continue to strengthen our business through an unwavering focus on the fundamentals and disciplined execution, and we are encouraged by our performance in areas like clinical quality and operational excellence. This focus gives us confidence in our ability to achieve our goal of returning to appropriate margins while at the same time driving continuous improvement and delivering even better experiences and outcomes for the members who count on us.
Outstanding clinical quality performance
Our 2027 Star Ratings results demonstrate excellence across several key clinical quality measures.
Aetna achieved an outstanding score on Plan All-Cause Readmissions (4.77* out of 5 stars), showcasing the strength of our care coordination programs, provider partnerships and focus on helping members successfully transition between care settings. Keeping members out of the hospital is one of the most important indicators of health care quality.
Our high-performing scores on Care for Older Adults Medication Review (5.00*) and Care for Older Adults Functional Status Assessment (4.03*) demonstrate the support we provide members in managing their health and maintaining their independence.
Reinforcing our commitment to early detection and preventive care, we earned strong scores on preventive screening measures, including Colorectal Cancer Screening (4.19*) and Breast Cancer Screening (4.07*).
Delivering a high-quality member experience
Aetna also delivered exceptional results on measures related to member experience and the quality of our customer support.
Low rates of Complaints about the Drug Plan (4.29*) demonstrate members' confidence in our service and commitment to resolving issues quickly and effectively.
Strong performance on Customer Service (4.04*), Getting Needed Care (3.89*) and Getting Needed Prescription Drugs (4.07*) further highlight our focus on making health care easier to access and navigate.
Aetna earned a high score on Rating of Health Care Quality (4.22*), indicating the positive experiences members had with their health care providers and the broader care experience supported by Aetna.
In addition, we demonstrated operational excellence through outstanding performance in service and administrative measures, including Call Center Foreign Language Interpreter and Teletypewriter Availability (4.99*), Reviewing Appeals Decisions (4.08*), Plan Makes Timely Decisions About Appeals (4.01*) and Drug Price Accuracy (4.01*). These results underscore our commitment to providing accurate information, fair processes, timely decisions and accessible support for every member.
Every year, Medicare evaluates plans based on a 5-star rating system. The Star Ratings are posted at Medicare.gov. Visit AetnaMedicare.com to learn more about the 2027 Aetna Medicare plans. Or call 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2026. A licensed agent may answer your call.
NOTE: Information in this release is based on 2027 Star Ratings data published by CMS on October 8, 2026, and MA and MAPD enrollment as of September 2026. Individual plan ratings may vary.
*FOR STAR RATING MEASURE SCORES: All scores are based on a rating scale of five stars.
About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
About Aetna
Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com.
Aetna Medicare is a HMO, PPO plan with a Medicare contract. Our SNPs also have contracts with State Medicaid programs. Enrollment in our plans depends on contract renewal. See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.
To send a complaint to Aetna, call the Plan or the number on your member ID card. To send a complaint to Medicare, call 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week. If your complaint involves a broker or agent, be sure to include the name of the person when filing your grievance.
©2026 Aetna Inc.
Media contact
Phil Blando
Phillip.blando@cvshealth.com
Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com
Y0001_9425651a_2027_M
Featured Image
Type of Content
Press Release
Oct 9 · 18:31·3BL Media
Energy · Biotech & pharma
LGF Lab Gas Flow, a manufacturer of laboratory infrastructure, has released its integrated Ultra-High Purity Gas Delivery Systems and Laboratory Gas Scrubber Systems. Designed for scientific research, biotechnology, and semiconductor fabrication, this equipment provides contamination control, operational safety, and environmental compliance.
Oct 9 · 17:44·GlobeNewswire
Healthcare · Biotech & pharma
ANN ARBOR, Mich., October 09, 2026--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and
Oct 9 · 17:20·Business Wire
Finance · Biotech & pharma
BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib
Oct 9 · 17:15·Business Wire
Healthcare · Biotech & pharma
BOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress
Oct 9 · 17:00·Business Wire
AI · Healthcare
Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation
Tue, 10/13/2026 - 08:00
Body
Originally published on preventcancer.org
This post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Gala.
Can AI help close care gaps in lung cancer?
Lung cancer remains the leading cause of cancer death in the United States, with the American Cancer Society projecting about 229,000 new diagnoses and 125,000 deaths in 2026 alone. Behind those numbers lies another part of the story: Medically underserved communities, including many rural areas, experience higher mortality rates for lung cancer and are also less likely to undergo routine screening or biomarker testing.
At Bristol Myers Squibb (BMS), we believe artificial intelligence (AI) can help identify and quantify these health care gaps, accelerate individual diagnosis, detect disparities in treatment pathways, predict risk of outcomes and proactively target interventions. Two ongoing collaborations help demonstrate this approach.
Catching cancer earlier
BMS shares the Prevent Cancer Foundation’s goal to increase awareness about the importance of lung cancer screening to enable earlier detection and better outcomes. However, lung cancer nodules can be small and easily overlooked, and they are sometimes found by chance on imaging done for unrelated reasons. Even when a nodule is spotted, more than half of these patients don’t receive proper follow-up care and may never actually see a specialist.
These challenges present an opportunity for improvement that BMS is tackling through our collaboration with Microsoft. Using AI algorithms that are cleared by the U.S. Food and Drug Administration (FDA), and deployed through Microsoft’s extensive Precision Imaging Network, will help radiologists analyze X-ray and CT images to flag hard-to-detect nodules. Then, workflow tracking tools will help ensure patients flagged with nodules are connected to care rather than fall through the cracks. This multi-year collaboration is currently in its first phase, recruiting pilot sites such as rural hospitals and community clinics.
Supporting better treatment decisions after diagnosis
A second opportunity begins after diagnosis. For patients with advanced non-small cell lung cancer (the most common form of lung cancer), selecting the most effective therapy depends on biomarker testing. These lab analyses identify specific genetic mutations driving a patient’s cancer. But biomarker testing doesn’t always happen as guidelines recommend, in part because lab and electronic health record systems are often disconnected.
Through our collaboration with Tempus AI, BMS implemented the AI-enabled Tempus Next Pathways program across 13 community-based health systems to build a near real-time view of the patient journey, finding out where and why patients were not receiving the right care according to guidelines.
The results were compelling. By providing these insights to clinical teams, guideline-directed biomarker testing rates rose from 73% to 84% across participating sites. The program also helped explain the reasons behind that gap, such as clinical factors like disease progression or transitions to hospice care, or logistical issues like patients relocating out of their previous health system. This information provided better tools to design targeted interventions.
Two projects, one purpose
Together, these two projects present a picture of what AI-enabled, data-driven and access-focused cancer care can look like: identifying cancer earlier through smarter imaging workflows and enabling evidence-based treatment. For BMS, that combination reflects a broader commitment, one shared with organizations like the Prevent Cancer Foundation, to help innovation in cancer care reach every community.
Learn more about Advancing population health – Bristol Myers Squibb
Canonical URL
https://preventcancer.org/article/advancing-access-to-lung-cancer-care-through-…
Featured Image
Type of Content
Article
Oct 9 · 15:48·3BL Media
Healthcare · Biotech & pharma
WALTHAM, Mass., October 09, 2026--Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So
Oct 9 · 12:30·Business Wire
Healthcare · Biotech & pharma
MONTPELLIER, France, October 09, 2026--Medincell (Paris:MEDCL) Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer questions from analysts.
Oct 9 · 12:14·Business Wire
Healthcare · Biotech & pharma
ZAMUDIO, Spain, October 09, 2026--Oncomatryx, the Basque biopharmaceutical company pioneering the treatment of solid tumors through their microenvironment, has taken part, together with German research institutions, in a study showing in patient tumor tissue that destroying the cells that protect the tumor also kills cancer cells.
Oct 9 · 12:07·Business Wire
Healthcare · Biotech & pharma
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR
Oct 9 · 12:00·GlobeNewswire